VR Logo

Janux Therapeutics Inc. (JANX) download report


Healthcare | Biotechnology & Pharma Research

Janux Therapeutics Inc. (JANX) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer.

IPO Date: 11-Jun-2021

Pres, CEO & Director: Dr. David Alan Campbell Ph.D.

Chief Scientific Officer: Dr. Shahram Salek-Ardakani Ph.D.

Listing: NASDAQ: JANX

Country: United States

Headquarters: La Jolla, CA

Website: https://www.januxrx.com

Key Facts

Market cap: $541.60 Mln

Revenue (TTM): $3.21 Mln

Earnings (TTM): $-43.80 Mln

Cash: $361.20 Mln

Total Debt: $0.15 Mln

Insider's Holding: 11.01%

Liquidity: Low

52 Week range: $9.39 - 35.93

Shares outstanding: 41,629,400

Stock Performance

Time Period Janux Therapeutics (JANX) S&P BSE Sensex S&P Small-Cap 600
YTD-34.26-8.74-17.05
1 month17.91-2.01-4.75
3 months-10.61-7.32-12.65
1 Year-47.680.45-16.28
3 Years--10.328.01
5 Years--11.296.35
10 Years--12.1410.55
As on 27-Jun-2022